2023-11-15 09:07:31 ET
DENVER, Colo., Nov 15, 2023 ( www.247marketnews.com )- SciSparc Ltd. (NASDAQ: SPRC) reported, this morning, positive topline results from its investigator-initiated Phase IIa trial, indicating that SciSparc’s proprietary SCI-110 provided a safe and effective solution for alleviating agitation in elderly Alzheimer’s patients who participated.
SciSparc is trading at $6.96, up $2.60 (+59.63%), on 2.33M premarket shares.
Its 52-week range is $2.80 to $34.58. It’s pulled well back from this morning’s $8.99 premarket high and has a history of short-term pops, plus it’s a foreign based listing, so swing or scalp is the mindset. If its strong trading volume continues, it may be an interesting morning trade.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering …
The post SciSparc Reports Positive Phase II Trial Results on Alzheimer’s Agitation appeared first on 24/7 Market News .
For further details see:
SciSparc Reports Positive Phase II Trial Results on Alzheimer’s Agitation